CLINICAL_TRIALS
trial_result
· 2019-05-31
Clinical Trial Update: Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis [Phase 3]
Summary
Phase 3 trial of sirukumab in giant cell arteritis was terminated; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Giant Cell Arteritis | Phase 3 | Status: TERMINATED | Results posted: 2019-05-31